AEON Biopharma (AEON) risk factors
Item 1A of every AEON Biopharma, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors53 risks8 new17 dropped11 reworded
AEON Biopharma relies entirely on obtaining FDA approval for ABP-450 as a biosimilar to Botox. Development requires navigating complex 351(k) pathways, litigation risks, and strict compliance standards.
Filed Mar 30, 2026 - FY2024 10-K risk factors62 risks
Clinical-stage biopharmaceutical company dependent entirely on the regulatory approval and commercialization of ABP-450 as a biosimilar to Botox. Relies heavily on exclusive licensing and supply agreements with Daewoong for ABP-450 manufacturing and distribution. Faces significant financial risk with limited operating history, only five employees, and substantial accumulated losses.
Filed Mar 24, 2025